Bafna Pharmaceuticals Limited

NSE BAFNAPH.NS

Bafna Pharmaceuticals Limited Debt to Equity Ratio for the year ending March 31, 2024: 0.30

Bafna Pharmaceuticals Limited Debt to Equity Ratio is 0.30 for the year ending March 31, 2024, a -3.33% change year over year. Debt to equity ratio represents the financing from debt versus equity. Higher ratio indicates more debt reliance, suggesting potential risk.

Bafna Pharmaceuticals Limited Debt to Equity Ratio for the year ending March 31, 2023 was 0.31, a 117.01% change year over year.
Bafna Pharmaceuticals Limited Debt to Equity Ratio for the year ending March 31, 2022 was 0.14, a -48.28% change year over year.
Bafna Pharmaceuticals Limited Debt to Equity Ratio for the year ending March 31, 2021 was 0.28, a 371.01% change year over year.
Bafna Pharmaceuticals Limited Debt to Equity Ratio for the year ending March 31, 2020 was 0.06, a -97.57% change year over year.

Key data

Date	Debt to Equity Ratio	Debt to Income Ratio	Debt to Tangible Net Worth Ratio	Dividend Coverage Ratio

NSE: BAFNAPH.NS

Bafna Pharmaceuticals Limited

CEO	Mr. Bansilal Mahaveer Chand Bafna
IPO Date	Nov. 12, 2012
Location	India
Headquarters	Bafna Towers
Employees	363
Sector	Healthcare
Industries Drugstores & Retail Pharmacies Chemicals & Advanced Materials Clinical Trials Pharmaceuticals

Description

Bafna Pharmaceuticals Limited manufactures and sells finished pharmaceutical formulations in India. The company provides delayed and sustained release, chewable, and orally disintegrating tablets. It also exports its products. Bafna Pharmaceuticals Limited was founded in 1981 and is based in Chennai, India.

Key trends

Past 5 years